O. Rosen

3.0k total citations
17 papers, 427 citations indexed

About

O. Rosen is a scholar working on Hematology, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, O. Rosen has authored 17 papers receiving a total of 427 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Hematology, 8 papers in Oncology and 5 papers in Public Health, Environmental and Occupational Health. Recurrent topics in O. Rosen's work include Acute Lymphoblastic Leukemia research (5 papers), Hematopoietic Stem Cell Transplantation (4 papers) and Chronic Myeloid Leukemia Treatments (3 papers). O. Rosen is often cited by papers focused on Acute Lymphoblastic Leukemia research (5 papers), Hematopoietic Stem Cell Transplantation (4 papers) and Chronic Myeloid Leukemia Treatments (3 papers). O. Rosen collaborates with scholars based in Germany, United States and Canada. O. Rosen's co-authors include Gero Massenkeil, Bernd Dörken, R. Arnold, Isabelle Genvresse, Marion Nagy, R Arnold, Christoph Lutz, Stefan Neuburger, Ingo Tamm and W. Reisinger and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Annals of the Rheumatic Diseases.

In The Last Decade

O. Rosen

17 papers receiving 416 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
O. Rosen Germany 11 236 148 106 102 68 17 427
AP Schwarer Australia 11 296 1.3× 187 1.3× 42 0.4× 97 1.0× 44 0.6× 17 481
Takayoshi Tachibana Japan 13 330 1.4× 112 0.8× 94 0.9× 90 0.9× 57 0.8× 81 530
H-S Chi South Korea 11 476 2.0× 117 0.8× 217 2.0× 80 0.8× 38 0.6× 15 541
Pablo Parker United States 9 472 2.0× 286 1.9× 174 1.6× 148 1.5× 66 1.0× 10 741
Anne‐Marie Manel France 10 141 0.6× 78 0.5× 88 0.8× 64 0.6× 54 0.8× 21 333
Tohru Sakura Japan 14 380 1.6× 102 0.7× 101 1.0× 89 0.9× 89 1.3× 32 579
A Ferrant Belgium 13 342 1.4× 175 1.2× 130 1.2× 60 0.6× 110 1.6× 27 624
Yasser Abou Mourad Canada 11 152 0.6× 181 1.2× 89 0.8× 20 0.2× 67 1.0× 41 348
Yoshiko Matsuhashi Japan 12 336 1.4× 147 1.0× 73 0.7× 117 1.1× 77 1.1× 41 521
Mario Ojeda‐Uribe France 11 164 0.7× 99 0.7× 136 1.3× 159 1.6× 111 1.6× 34 486

Countries citing papers authored by O. Rosen

Since Specialization
Citations

This map shows the geographic impact of O. Rosen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by O. Rosen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites O. Rosen more than expected).

Fields of papers citing papers by O. Rosen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by O. Rosen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by O. Rosen. The network helps show where O. Rosen may publish in the future.

Co-authorship network of co-authors of O. Rosen

This figure shows the co-authorship network connecting the top 25 collaborators of O. Rosen. A scholar is included among the top collaborators of O. Rosen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with O. Rosen. O. Rosen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
2.
George, Suzanne, Michael C. Heinrich, Ping Chi, et al.. (2018). Initial results of phase I study of DCC-2618, a broad-spectrum KIT and PDGFRa inhibitor, in patients (pts) with gastrointestinal stromal tumor (GIST) by number of prior regimens. Annals of Oncology. 29. viii576–viii577. 19 indexed citations
3.
Jankú, Filip, A.R. Abdul Razak, Michael S. Gordon, et al.. (2017). Encouraging activity of novel pan-KIT and PDGFRα inhibitor DCC-2618 in patients (pts) with Gastrointestinal Stromal Tumor (GIST). Annals of Oncology. 28. v521–v521. 6 indexed citations
4.
Massenkeil, Gero, Tobias Alexander, O. Rosen, et al.. (2016). Long-term follow-up of fertility and pregnancy in autoimmune diseases after autologous haematopoietic stem cell transplantation. Rheumatology International. 36(11). 1563–1568. 20 indexed citations
5.
George, Suma, A.R. Abdul Razak, David G. Brooks, et al.. (2016). DCC-2618, a pan KIT and PDGFR switch control inhibitor, achieves proof-of-concept in a first-in-human study. European Journal of Cancer. 69. S4–S4. 3 indexed citations
6.
McClung, Michael R., Arkadi Chines, Jacques P. Brown, et al.. (2015). OP0251 Effects of 2 Years of Treatment with Romosozumab Followed by 1 Year of Denosumab or Placebo in Postmenopausal Women with Low Bone Mineral Density. Annals of the Rheumatic Diseases. 74. 166–167. 21 indexed citations
7.
Hurwitz, Herbert I., Pamela S. Douglas, G. W. Sledge, et al.. (2010). Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV).. Journal of Clinical Oncology. 28(15_suppl). 3039–3039. 39 indexed citations
8.
Lutz, Christoph, Gero Massenkeil, Marion Nagy, et al.. (2008). A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation. 41(9). 805–812. 39 indexed citations
9.
Massenkeil, Gero, Marion Nagy, Stefan Neuburger, et al.. (2005). Survival after reduced-intensity conditioning is not inferior to standard high-dose conditioning before allogeneic haematopoietic cell transplantation in acute leukaemias. Bone Marrow Transplantation. 36(8). 683–689. 38 indexed citations
10.
Arnold, R, Cathleen Lutz, Stefan Neuburger, et al.. (2005). Allogeneic stem cell transplantation (allo SCT) in adult ALL: Does prophylactic donor lymphocyte infusion (DLI) improve survival?. Biology of Blood and Marrow Transplantation. 11(2). 2–2. 4 indexed citations
11.
Hoffend, Johannes, Michael Eisenhut, F. Xavier Bosch, et al.. (2004). Uptake of the anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 in tumors of subjects with head and neck squamous cell carcinoma (HNSCC). Journal of Clinical Oncology. 22(14_suppl). 3043–3043. 3 indexed citations
12.
Hoffend, Johannes, Michael Eisenhut, F. Xavier Bosch, et al.. (2004). Uptake of the anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 in tumors of subjects with head and neck squamous cell carcinoma (HNSCC). Journal of Clinical Oncology. 22(14_suppl). 3043–3043. 3 indexed citations
13.
Rosen, O., H.-J. Müller, Nicola Gökbuget, et al.. (2003). Pegylated asparaginase in combination with high‐dose methotrexate for consolidation in adult acute lymphoblastic leukaemia in first remission: a pilot study. British Journal of Haematology. 123(5). 836–841. 30 indexed citations
14.
Massenkeil, Gero, Marion Nagy, O. Rosen, et al.. (2003). Reduced intensity conditioning and prophylactic DLI can cure patients with high-risk acute leukaemias if complete donor chimerism can be achieved. Bone Marrow Transplantation. 31(5). 339–345. 61 indexed citations
15.
Massenkeil, Gero, et al.. (2002). Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplantation. 30(12). 899–903. 79 indexed citations
16.
Rosen, O., Gero Massenkeil, Falk Hiepe, et al.. (2001). Cardiac death after autologous stem cell transplantation (ASCT) for treatment of systemic sclerosis (SSc): no evidence for cyclophosphamide-induced cardiomyopathy. Bone Marrow Transplantation. 27(6). 657–658. 14 indexed citations
17.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by AP Schwarer Breakdown of academic impact, for papers by Takayoshi Tachibana Breakdown of academic impact, for papers by H-S Chi Breakdown of academic impact, for papers by Pablo Parker Breakdown of academic impact, for papers by Anne‐Marie Manel Breakdown of academic impact, for papers by Tohru Sakura Breakdown of academic impact, for papers by A Ferrant Breakdown of academic impact, for papers by Yasser Abou Mourad Breakdown of academic impact, for papers by Yoshiko Matsuhashi Breakdown of academic impact, for papers by Mario Ojeda‐Uribe
Rankless by CCL
2026